PlumX Metrics
Embed PlumX Metrics

Nurses' roles in CAR-T therapy for B-cell malignancies and managing associated cytokine release syndrome

Asia-Pacific Journal of Oncology Nursing, ISSN: 2347-5625, Vol: 11, Issue: 2, Page: 100367
2024
  • 0
    Citations
  • 0
    Usage
  • 14
    Captures
  • 1
    Mentions
  • 3
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

  • Captures
    14
  • Mentions
    1
    • News Mentions
      1
      • News
        1
  • Social Media
    3
    • Shares, Likes & Comments
      3
      • Facebook
        3

Most Recent News

Connecting Patients With Multiple Myeloma to Larger Institutions for CAR T-Cell Therapy

Nurses at local and specialized centers can work together to create a pathway for patients throughout treatment. Over the 30 years Beth Faiman, PhD, MSN,

Review Description

In recent times, significant innovations have been made in cancer immunotherapy. These innovations have yielded positive outcomes, including a substantial improvement in the clinical outcomes of cancer patients, especially in the B-cell setting involving patients with B-cell malignancies. This paper explores oncology nurses’ actual and expanded roles in utilizing chimeric antigen receptor T-cell (CAR-T) therapy. CAR-T therapy is an exciting innovation in cancer treatment. However, this therapy is often associated with some mild to life-threatening side effects and toxicities, including cytokine release syndrome (CRS). Unfortunately, nurses lack adequate standardized guidelines for monitoring and managing patients with CRS. This paper explains oncology nurses’ actual and expanded roles in utilizing CAR-T therapy in treating B-cell malignancies based on experience and published data. Nurses’ responsibilities for patients experiencing CAR-T toxicities with a particular focus on CRS during treatment are discussed.

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know